FDA OK makes As­traZeneca the leader in one new seg­ment of the all-im­por­tant lung can­cer mar­ket

As­traZeneca $AZN has found a way to jump out in front of a pack of heavy­weight PD-1/L1 ri­vals duk­ing it out for a big piece of the block­buster lung can­cer mar­ket.

The day af­ter Pfiz­er and Mer­ck KGaA were forced to throw in the tow­el on a piv­otal sec­ond-line lung can­cer study for Baven­cio, the FDA hand­ed the UK phar­ma gi­ant an ap­proval to mar­ket Imfinzi to pa­tients whose stage III non-small cell lung can­cer hasn’t pro­gressed af­ter chemora­di­a­tion and whose tu­mors can’t be sur­gi­cal­ly re­moved.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.